Advertisement
Table 1 Patient selection for methotrexate (MTX) and biologics/tofacitinib (B/T) cohorts
| Inclusion/exclusion criteria | Number of patients for MTX cohort | Number of patients for B/T cohort |
|---|---|---|
| Patients with two RA inpatient/outpatient diagnoses 7 days apart and within 12 months of each other in claims; age ≥ 18 years at first such RA diagnosis | 49,606 | 49,606 |
| Requiring ≥ 1 prescriptions of corresponding drugs from EHR at or after first RA diagnosis (first prescription defined as index prescription) | 8025 | 5129 |
| Requiring ≥ 12 months before index and ≥ 2 (for MTX) or ≥ 3 (for B/T) months after index of continuous medical and pharmacy benefits coverage (≤ 45 days of insurance gap allowed) | 2401 | 1266 |
| Excluding patients with filling or administration of corresponding drugs in claims during 12+ months before index | 968 | 483 |
| Excluding patients with RA-related hospitalizations in claims within 2 (MTX) or 3 (B/T) months after index prescription | 955 | 476 |
| Excluding patients with B/T fills or administration in pharmacy and medical claims during 12+ months before index (i.e., biologic naïve) | 848 | – |
| Excluding patients with ≥ 2 diagnoses of psoriasis or psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, or cancer (excluding nonmelanoma skin cancer) in claims during 12+ months before index (final sample size) | 763 | 434 |
